Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
2007, Journal of Cystic Fibrosis
2008 •
2008 •
American Journal of Respiratory and Critical Care Medicine
Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis2010 •
American Journal of …
Ataluren (PTC124) induces CFTR protein expression and activity in children with nonsense mutation cystic fibrosis2010 •
"Background: Topiramate and zonisamide are used as anticonvulsant medications in children, and Topiramate is also used for migraine prophylaxis. There are reports of topiramate and zonisamide causing oligohydrosis as a side-effect (Clin Neuropharmacol 2008; 31: 339-346, Pediatr Neurol 2003; 28: 184-189), but their effect on sweat chloride levels has not been studied systematically (Indian Pediatr 2008; 45: 238-240). Hypothesis: Topiramate and zonisamide not only reduce sweat production, but they can also cause elevation of sweat electrolytes. Methods: Eighteen patients who were receiving topiramate or zonisamide therapy for at least 6 months were enrolled either from Neurology outpatient clinic or Epilepsy Monitoring Unit, and were only included in the study if they had no signs or symptoms and a negative family history of cystic fibrosis. Patients underwent pilocarpine iontopheresis and sweat collection via Macroduct system (Wescor Inc., Logan, UT) as per Clinical and Laboratory Standards Institute (CLSI) and Cystic Fibrosis Foundation (CFF) guidelines. The samples were analyzed the same day using a chloridometer and the mean sweat chloride values were compared to published normative data (J Pediatr 2008; 153: 758-63) by Student’s t-test. Results: Of the 18 pts (age range 3-22 years, mean age 9.94 years, sex ratio M:F = 0.44) that were enrolled for this study, 14 adequate samples (>15 µL volume) could be obtained from left arm, and 13 from right arm. There were 14 patients on topiramate and 4 were receiving zonisamide. The mean sweat chloride level was 41.77 ± 18.71 mEq/L from the left arm and 46.475 ± 19.29 mEq/L from the right arm for patients receiving topiramate. For patients on Zonisamide therapy, the mean sweat chloride level was 29.83 ± 10.00 mEq/L from the left arm, and 36.5 ± 3.54 mEq/L from the right arm. Sweat chloride values and volumes did not correlate with dose of either anticonvulsant (p=0.5). Overall 7/14 (50%) patients on topiramate or zonisamide had either a borderline (> 40 mEq/L but < 60 mEq/L) or elevated (> 60 mEq/L) sweat chloride test result. Comparing these results to the standard reference values for sweat chloride in the normal population, the mean sweat chloride level of patients on topiramate was noted to be significantly higher (p<0.001) for both arms. There was no significant difference in the mean values for sweat chloride between the topiramate and zonisamide groups for both sides (p>0.05). The insufficient sweat collection rate was 3/18 (17%) for both arms, and another 3/18 had insufficient sweat collected from one of the arms. This rate is much higher than the goal of <5% inadequate sweat collection rate that is established by CFF for accredited sweat testing laboratories, and suggests that drug-induced oligohydrosis is operative in this patient population. Conclusions: Topiramate and zonisamide can not only cause oligohydrosis, but they can also elevate sweat chloride levels in patients with no clinical features of cystic fibrosis. Further studies to explore whether this is due to interaction with CFTR or via a different mechanism, are underway."
Since the first description of Cystic fibrosis (CF) more than 75 y ago, significant advances have been made in understanding its pathogenesis and in developing specific therapies. The pace of these developments was further accelerated after the discovery of CF gene in 1989 and since then, CF has been transformed from being a pediatric illness into a chronic life-limiting genetic disorder with survival up to the fourth decade. The development of mutation-specific therapies in the first decade of the 21st century has the potential to change the natural history of CF and has now ushered in the era of 'Precision Medicine'. The ability to revert the basic defect in CF by using Personalized Medicine approach based on each individual's genetic profile will serve as a model for other chronic disorders as well. This review highlights the recent advances in the field of CF research that have led to a paradigm shift in its management and outcomes.
2019 •
Journal of Translational Medicine
Cystic fibrosis: current therapeutic targets and future approaches2017 •
Clinical Pulmonary Medicine
The Clinical and Research Utility of Bronchoscopy in Cystic Fibrosis2019 •
Journal of Cystic Fibrosis
Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy2010 •
Clinical Biochemistry
Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapy2012 •
Journal of Clinical Investigation
Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin2007 •
2011 •
2007 •
Paediatric Respiratory Reviews
Primary ciliary dyskinesia: prospects for new therapies, building on the experience in cystic fibrosis2009 •
International Journal of Molecular Sciences
Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems2020 •
Molecular biology of the cell
From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations2016 •
Expert Opinion on Orphan Drugs
Cystic fibrosis treatment: targeting the basic defect2017 •
American Journal of Respiratory and Critical Care Medicine
Chloride Transport in Nasal Ciliated Cells of Cystic Fibrosis Heterozygotes2005 •
American journal of respiratory and critical care medicine
Discovery of Clinically Approved Agents That Promote Suppression of CFTR Nonsense Mutations2016 •
Frontiers in Bioengineering and Biotechnology
Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis2019 •
International Journal of Molecular Sciences
Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations2020 •
International Journal of Molecular Sciences
Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene2021 •
The Clinical biochemist. Reviews
The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era2005 •
Translational Research
Translating the genetics of cystic fibrosis to personalized medicine2015 •
European Journal of Medicinal Chemistry
Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs2018 •
2012 •
Therapeutic advances in respiratory disease
New and investigational treatments in cystic fibrosis2011 •
Gastroenterology
CFTR Cl− channel function in native human colon correlates with the genotype and phenotype in cystic fibrosis2004 •
2014 •
Pediatric Pulmonology
A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis andPseudomonas aeruginosa infection2008 •
Nucleic Acids Research
Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors2021 •
Journal of pediatric gastroenterology and nutrition
Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR function2016 •
European Journal of Medicinal Chemistry
Pharmacological approaches for targeting cystic fibrosis nonsense mutations2020 •